2023
Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors
Gottlieb J, Fischer B, Schupp J, Golpon H. Calcineurin-inhibitor free immunosuppression after lung transplantation – a single center case-control study in 51 patients converted to Mechanistic Target of Rapamycin (mTOR) inhibitors. PLOS ONE 2023, 18: e0284653. PMID: 37200246, PMCID: PMC10194991, DOI: 10.1371/journal.pone.0284653.Peer-Reviewed Original ResearchConceptsCNI-free immunosuppressionCalcineurin inhibitor-free immunosuppressionMTOR inhibitorsFree immunosuppressionLung transplantationImproved survivalRapamycin inhibitorsNeurological diseasesSingle-center case-control studyCenter case-control studyCNI-free regimenCurative treatment optionGlomerular filtration rateMajority of patientsNon-malignant indicationsSignificant functional improvementCase-control studyMechanistic targetAcute rejectionLTx patientsNeurological complicationsAdult patientsMedian durationSingle centerTreatment options
2021
Abnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients
Frye B, Potasso L, Farin E, Fichtner U, Birring S, Müller-Quernheim J, Schupp J. Abnormal FeV1 and body mass index are associated with impaired cough-related quality of life in sarcoidosis patients. Respiratory Medicine 2021, 188: 106600. PMID: 34530353, DOI: 10.1016/j.rmed.2021.106600.Peer-Reviewed Original ResearchMeSH KeywordsAdultBody Mass IndexCoughFemaleForced Expiratory VolumeHumansMaleQuality of LifeRetrospective StudiesSarcoidosisConceptsLeicester Cough QuestionnaireCough-related qualityQuality of lifeSarcoidosis patientsLCQ scoreBody mass indexAbnormal FEV1Routine followLung functionOrgan impairmentTreatable traitsMass indexDisease burdenGranulomatous diseaseFEV1PatientsSarcoidosisBMIScoresQuestionnaireLungCohortFollowDiseaseLifeBronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease
Friedmann D, Unger S, Keller B, Rakhmanov M, Goldacker S, Zissel G, Frye B, Schupp J, Prasse A, Warnatz K. Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease. Frontiers In Immunology 2021, 11: 616832. PMID: 33613543, PMCID: PMC7892466, DOI: 10.3389/fimmu.2020.616832.Peer-Reviewed Original ResearchMeSH KeywordsB-LymphocytesBronchoalveolar Lavage FluidCommon Variable ImmunodeficiencyHumansLung Diseases, InterstitialRetrospective StudiesSarcoidosisTh1 CellsConceptsInterstitial lung diseaseCommon variable immunodeficiencyBAL fluidB cellsLung diseaseT cellsImmune dysregulationBronchoalveolar lavageHealthy donorsClass-switched memory B cellsLymphocytic interstitial lung diseaseProgressive interstitial lung diseaseLevels of BAFFLike cell subsetSystemic immune dysregulationRegulatory T cellsVideo-assisted thoracoscopyBronchoalveolar lavage fluidT cell populationsPotential immune mechanismsLevels of APRILMemory B cellsB cell interactionsFlow cytometric profilingPotential treatment target
2019
The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals
Frye B, Schupp J, Rothe M, Köhler T, Prasse A, Zissel G, Vach W, Müller‐Quernheim J. The value of bronchoalveolar lavage for discrimination between healthy and diseased individuals. Journal Of Internal Medicine 2019, 287: 54-65. PMID: 31612575, DOI: 10.1111/joim.12973.Peer-Reviewed Original ResearchBAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis
Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N. BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2019, 199: 622-630. PMID: 30141961, PMCID: PMC6396865, DOI: 10.1164/rccm.201712-2551oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisAirway basal cellsChronic obstructive pulmonary diseaseObstructive pulmonary diseasePulmonary diseaseBAL cellsBasal cellsPulmonary fibrosisControl subjectsCell gene expressionIndependent IPF cohortsNine-gene signatureIPF cohortDerivation cohortClinical parametersRetrospective studyUnivariate analysisUnpredictable courseCell involvementDiscovery cohortGene expressionHealthy volunteersCox modelStage IIIFatal disease
2016
Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases
Schupp J, Köhler T, Müller-Quernheim J. Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases. Respiration 2016, 91: 296-301. PMID: 27082957, DOI: 10.1159/000445031.Peer-Reviewed Original ResearchConceptsNon-specific interstitial pneumoniaInterstitial lung diseaseLymphocytic interstitial pneumoniaCyclophosphamide pulse therapyLung functionPulse therapyInterstitial pneumoniaLung diseaseRheumatoid arthritis-associated interstitial lung diseaseIdiopathic non-specific interstitial pneumoniaFibrotic interstitial lung diseaseProgressive lung function declineBetter survival outcomesLung function declineIdiopathic pulmonary fibrosisBronchoalveolar lavage cytologyGroup of disordersILD patientsMost patientsSystemic sclerosisTotal cohortFunction declineLavage cytologyPulmonary fibrosisCyclophosphamide treatment